Reduction of the viral load of HIV-1 after the intraperitoneal administration of dextrin 2-sulphate in patients with AIDS

AIDS

Volumn 12, Issue 4, 1998, Pages 399-409

  Shaunak, Sunil ^b   Thornton, Mark ^b   John, Stephanie ^b   Teo, Ian ^b   Peers, Elizabeth ^a   Mason, Philip ^b   Krausz, Thomas ^b   Davies, Donald S ^b  

^a Blaby Hall ^*  (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

AIDS; Dextrin 2 sulphate; Intraperitoneal chemotherapy; Kaposi's sarcoma; Lymphatic circulation; Macrophage; Macrophage inflammatory protein (MIP) 1 ; MIP 1 ; Sulphated polysaccharides; Viral load

Indexed keywords

ANTIGEN P24; CHEMOKINE; CHEMOKINE RECEPTOR; DEXTRIN; DEXTRIN 2 SULFATE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRAPERITONEAL DRUG ADMINISTRATION; KAPOSI SARCOMA; PERITONEUM MACROPHAGE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECEPTOR BLOCKING; VIRUS LOAD; VIRUS REPLICATION;

EID: 0032485443     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199804000-00009     Document Type: Article

References (42)

1. Mitsuya H, Looney DJ, Kuno S, Ueno R, Wong-Staal F, Broder S: Dextran sulphate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science 1988, 240:645-649.
2. McClure MO, Moore JP, Blane DF, et al.: Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro. AIDS Res Hum Retrovirues 1992, 8:19-26.
3. Shaunak S, Cooderham NJ, Edwards RJ, et al.: Infection by HIV-1 blocked by binding of dextrin 2-sulphate to the cell surface of activated human peripheral blood mononuclear cells and cultured T-cells. Br J Pharmacol 1994, 113:151-158.
4. Javan CM, Gooderham NJ, Edwards RJ, Davies DS, Shaunak S: The anti-HIV-1 activity of sulphated derivatives of dextrin against primary viral isolates of HIV-1 in lymphocytes and monocyte-derived macrophages. AIDS Res Hum Retroviruses 1997, 13:875-880.
5. Abrams DJ, Kuno S, Wong R, et al.: Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med 1989, 110: 183-188.
6. Lorentsen KJ, Hendrix CW, Colling JM, et al.: Dextran sulfate is poorly absorbed after oral administration. Ann Intern Med 1989, 111:561 566.
7. Flexner C, Barditch-Crovo PA, Kornhauser DM, et al.: Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob Agents Chemother 1991, 35:2544-2550.
8. Shaunak S: Cell Surface Receptors for HIV [PhD Ihesis]. London: University of London; 1993.
9. Pantaleo G, Gaziosi C, Butini L, et al.: Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci USA 1991, 88:9838 9842.
10. Embretson J, Zupancic M, Ribas JL, et al.: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993, 362: 359-362.
11. Pantaleo G, Graziosi C, Demarest JF, et al.: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993, 362:355-358.
12. Hollinger FB, Bremer JW, Myers LE, Gold JW, McQuary L: Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J Clin Microbiol 1992, 30:1787 1794.
13. Japour AJ, Mayers DL, Johnson VA, et al.: Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1993, 37:1095-1101.
14. Fiscus SA, DeGruttola V, Gupta P, et al.: Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis 1995, 171:305-311.
15. De-Wolf F, Hogervorst E, Goudsmil J, et al.: Syncylium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. AIDS Ras Hum Retroviruses 1994, 10:1387-1400.
16. Rodriguez RJ, Dayhoff DE, Chang G, et al.: Comparison of serum and plasma viral RNA measurements in primary and chronic human immunodeficiency virus type 1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 15:49-53.
17. Shaunak S, Albriglit RE, Klotman ME, Henry SC, Bartlett JA, Hamilton JD: Amplification of HIV-1 provirus from cerebrospinal fluid and its correlation with neurologic disease. J Infect Dis 1990, 161:1068-1072.
18. Teo I, Veryard C, Barnes H, et al.: Circular forms of unintegrated HIV-1 DNA and high levels of viral protein expression: association with dementia and multinucleated giant cells in the brains of patients with AIDS. J Virol 1997, 71:2928-2933.
19. Paxton WB, Coombs RW, McElrath MJ, et al.: Longitudinal analysis of quantitative virologic measures in HIV-infected subjects: implications for applying measurements to individual patients. J Infect Dis 1997, 175:247-254.
20. Raboud JM, Montaner JSG, Rae S, Conway B, Singer J, Schechter MT: Issues in the design of trials of therapies for subjects with HIV infection that use plasma RNA level as an outcome. J Infect Dis 1997, 175:576-582.
21. Watson K: Characterisation of the Dextrin 2-Sulphate Cell Surface Binding Component [PhD Thesis]. London: University of London; 1997.
22. Javan C: Sulphated Dextrins and Primary Viral Isolates of HIV-1 [PhD Thesis]. London: University of London; 1997.
23. Davies DS: Kinetics of icodextrin. Perit Dial Int 1994, 14 (suppl 2):S45-S50.
24. Denis M, Ghadirian E: Mycobacterium avium infection in HIV-1 infected subjects increases monokine secretion and is associated with enhanced viral load and diminished immune response to viral antigens. Clin Exp Immunol 1994, 97:76-82.
25. Donovan RM, Bush CE, Markowitz, NP, Baxa DM, Saravolatz LD: Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. J Infect Dis 1996, 174:401-403.
26. Krown SE, Metroka C, Wernz JC: Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1989, 7:1201-1207.
27. Klinger MH, Wilhelm D, Bubel S, Sticherling M, Schroder JM, Kuhnel W: Immunocytochemical localisation of the chemokines RANTES and MIP-1 alpha within human platelets and their release during storage. Int Arch Allergy Immunol 1995, 107:541-546.
28. Kovacs JA, Vogel S, Albert JM, et al.: Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996, 335:1350-1356.
29. Beddows S, Bieniasz P, Shaunak S, Weber JN: HIV replication in CD4-negative cell lines: effect of cloning, CD4 expression and inhibition by dextrin 2-sulphate. Antiviral Chem Chemother 1993, 4:173-177.
30. Watson K, Edwards RJ, Shaunak S, et al.: Extra-nuclear location of histories in activated human peripheral blood lymphocytes and cultured T-cells. Biochem Pharmacol 1995, 50:299-309.
31. Deng H, Liu R, Ellmeier W, et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
32. Dragic T, Litwin V, Allaway CP, et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
33. Trkola A, Dragic T, Arthos J, et al.: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384:184-187.
34. Wu L, Gerard NP, Wyatt R, et al.: CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996, 384:179-183.
35. Verani A, Scarlatti G, Comar M, et al.: C-C chemokines released by lipopolysaccharide-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells. J Exp Med 1997, 185:805-816.
36. Andersson J, Andersson U: Characterization of cytokine production in infectious mononucleosis studied at a single-cell level in tonsil and peripheral blood. Clin Exp Immunol 1993, 92:7-13.
37. Nakamura S, Sakurada S, Salahuddin SZ, et al.: Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial cell wall complex. Science 1992, 255:1437-1440.
38. Baba M, Shigeta S, Ikeuchi T, Korenaga H, Osada Y: Anti-angiogenesis agent DS-4152 is a potent and selective inhibitor of HIV-1 replication in vitro. AIDS 1994, 8:43-48.
39. Dictor M, Andersson C: Lymphaticovenous differentiation in Kaposi's sarcoma. Cellular phenotypes by stage. Am J Pathol 1988, 130:411-417.
40. Dictor M: Kaposi's sarcoma. Origin and significance of lymphaticovenous connections. Virchows Arch 1986, 409:23-35.
41. Kaaya EE, Parravicini C, Ordonez C, et al.: Heterogeneity of spindle cells in Kaposi's sarcoma: comparison of cells in lesions and in culture. J Acquir Immune Defic Syndr Hum Retroviol 1995, 10:295-305.
42. Browning PJ, Sechler JM, Kaplan M, et al.: Identification and culture of Kaposi's sarcoma-like spindle cells from the peripheral blood of human immunodeficiency virus-1-infected individuals and normal controls. Blood 1994, 84:2711-2720.